CDMO Hovione and Industrial Design Consultancy (IDC) have announced that their new single-use capsule-based nasal delivery device is now available exclusively as part of an integrated platform that includes Hovione’s intranasal drug development and manufacturing services. The companies partnered in 2023 with plans for development of two capsule-based devices for intranasal delivery: the single-use device and a multidose device.
According to the announcement, the device “enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability,” and the companies say that integrated service offering “reduces the need for technology transfers, streamlines development, and provides a single platform for pharmaceutical partners.” Hovione’s capabilities include API development, particle engineering, formulation, and capsule filling in addition to devices.
Hovione VP, Strategic Business Management Márcio Temtem commented, “This milestone marks an important step in the evolution of our collaboration with IDC, from device innovation to a fully integrated intranasal drug delivery platform. As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.”
IDC’s Managing Director Stephen Knowles said, “Our partnership with Hovione has already delivered a successful single-use device suitable for a range of therapies and our joint team can support pharma customers to use the device to bring new nasal therapies to market. Additionally, we are now well advanced with the development of a multiuse device to support an even wider range of therapies and patient needs.”
Read the Hovione press release
